Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17
- PMID: 9014009
Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17
Abstract
It was investigated whether human antibody against HIV-1 protein p17 (anti-p17) in HIV carriers' plasma has the ability to neutralize the infectivity of HIV. By the pretreatment of HIV-1 with anti-p17 from HIV carriers, progeny HIV-1 production from cells infected with virus pretreated with anti-p17 was suppressed and/or delayed. The neutralizing activity of anti-p17 was decreased in the presence of recombinant p17. The latter obviously masked the neutralizing activity of anti-p17. The relevant epitope(s) on p17 is located apparently on the surface of HIV virions and the binding of anti-p17 to p17 impairs the infectivity of HIV. This implies that anti-p17, if stably present in HIV carriers' plasma, may also play an important role in reducing the infectivity of HIV-1 in vivo.
Similar articles
-
Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.J Gene Med. 2003 Mar;5(3):182-9. doi: 10.1002/jgm.336. J Gene Med. 2003. PMID: 12666184
-
Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.J Hum Virol. 2001 Nov-Dec;4(6):306-16. J Hum Virol. 2001. PMID: 12082397
-
Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.AIDS. 1993 Oct;7(10):1315-23. AIDS. 1993. PMID: 8267904
-
[Anti-HIV-1 p17 antibody as anti-HIV agent].Nihon Rinsho. 1993 Sep;51 Suppl:213-8. Nihon Rinsho. 1993. PMID: 8271386 Review. Japanese. No abstract available.
-
HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.Pharmacol Ther. 2010 Dec;128(3):433-44. doi: 10.1016/j.pharmthera.2010.08.005. Epub 2010 Sep 8. Pharmacol Ther. 2010. PMID: 20816696 Review.
Cited by
-
Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein.PLoS One. 2015 Jul 30;10(7):e0133509. doi: 10.1371/journal.pone.0133509. eCollection 2015. PLoS One. 2015. PMID: 26226263 Free PMC article.
-
Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone.PLoS One. 2013 Nov 29;8(11):e76104. doi: 10.1371/journal.pone.0076104. eCollection 2013. PLoS One. 2013. PMID: 24312165 Free PMC article.
-
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.J Virol. 1998 Dec;72(12):9656-67. doi: 10.1128/JVI.72.12.9656-9667.1998. J Virol. 1998. PMID: 9811699 Free PMC article.